Source: Google NewsPublished on 2021-02-16
Related Articles:
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- Psychosis Treatments October 28, 2019 Psychosis Treatments PSYCHOSIS TREATMENTS Generic Brand Form Indication Adult Initial Dose Adult Dose Titration First-Generation Antipsychotics chlorpromazine HCl — tabs Psychosis. Mania Less acutely disturbed: 25mg three times dailyOutpatient: 10mg 3–4 times daily or 25mg 2–3 times dailySevere cases: 25mg three times daily Inpatient: 500–1000mg/dayLess acutely disturbed: 400mg/dayOutpatient: 200–800mg/day Increase dose gradually until symptoms are controlled. Continue optimum dosage for…
- The drug development pipeline for Parkinson’s December 2, 2020 # # # # For a long time a regular request from SoPD readers has been to provide an overview of the clinical trial landscape for Parkinson’s, particularly in the area of drug development. Such projects are difficult, however, as the landscape is broad and dynamic – lots of different approaches being applied and new entrants continually entering the arena.…
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Copy Number Variant in the Region of Adenosine Kinase (ADK) and Its Possible Contribution to Schizophrenia Susceptibility. May 2, 2019 Copy Number Variant in the Region of Adenosine Kinase (ADK) and Its Possible Contribution to Schizophrenia Susceptibility. Int J Neuropsychopharmacol. 2018 05 01;21(5):405-409 Authors: Kimura H, Kushima I, Yohimi A, Aleksic B, Ozaki N Abstract Background: Adenosine kinase (ADK) is supposed to be a schizophrenia susceptibility gene based on the findings that ADK is an enzyme that catalyzes transfer of…
- Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders. January 7, 2021 Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders. Mov Disord. 2021 Jan 06;: Authors: Kuusimäki T, Al-Abdulrasul H, Kurki S, Hietala J, Hartikainen S, Koponen M, Tolppanen AM, Kaasinen V Abstract BACKGROUND: PD comorbid with schizophrenia has been considered rare because these diseases associate with opposite alterations in the brain dopamine system. The objective of this study…
- EVER Pharma Expands European Market for D-mine Pump for Delivering Parkinson’s Therapies July 9, 2019 D-mine Pump, a portable micro-infusion pump designed to continuously deliver therapies under the skin (subcutaneously) to patients with Parkinson’s disease, has received the European CE approval and now will be marketed in several European countries. CE means “European Conformity,” a certification mark that indicates conformity with European health, safety, and environmental protection standards. The D-mine pump, according to a press release from…
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- 2020 wish list January 10, 2020 Here at the Science of Parkinson’s, we don’t like making predictions – that’s a mug’s game. We would rather explore interesting ideas based around what we hope to see happen in 2020 – discussing different ways and means by which they could occur – in the hope that some one will pick up the ball and run with it…
- Unmet Needs of People With Parkinson's Disease and Their Caregivers During COVID-19-Related Confinement: An Explorative Secondary Data Analysis. February 5, 2021 Related ArticlesUnmet Needs of People With Parkinson's Disease and Their Caregivers During COVID-19-Related Confinement: An Explorative Secondary Data Analysis. Front Neurol. 2020;11:615172 Authors: Hanff AM, Pauly C, Pauly L, Schröder VE, Hansen M, Meyers GR, Kaysen A, Hansen L, Wauters F, Krüger R Abstract Self-perceived unmet needs in people with typical and atypical parkinsonism (PwP) and their caregivers, support network,…
- New Opportunities in Parkinson's disease Market 2019 Growth Overview, SWOT Analysis & Forecast to 2025 With Top Leaders are US WorldMeds LLC, Intec Pharma, Sunovion Pharma, Pharma Two B Ltd. - Market Expert October 15, 2019 New Opportunities in Parkinson's disease Market 2019 Growth Overview, SWOT Analysis & Forecast to 2025 With Top Leaders are US WorldMeds LLC, Intec Pharma, Sunovion Pharma, Pharma Two B Ltd. Market Expert
- New Opportunities in Parkinson's disease Market 2019 Growth Overview, SWOT Analysis & Forecast to 2025 With Top Leaders are US WorldMeds LLC, Intec Pharma, Sunovion Pharma, Pharma Two B Ltd. - Market Report Gazette November 5, 2019 New Opportunities in Parkinson's disease Market 2019 Growth Overview, SWOT Analysis & Forecast to 2025 With Top Leaders are US WorldMeds LLC, Intec Pharma, Sunovion Pharma, Pharma Two B Ltd. Market Report Gazette
- Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson's disease and schizophrenia. August 15, 2019 Related ArticlesEvaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson's disease and schizophrenia. Neuropsychiatr Dis Treat. 2019;15:2073-2085 Authors: Gupta AK, Pokhriyal R, Das U, Khan MI, Ratna Kumar D, Gupta R, Chadda RK, Ramachandran R, Goyal V, Tripathi M, Hariprasad G Abstract Background and objective: Dopamine…
- Monthly research review: February 2020 February 29, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- The Corporate Reputation of Neurological Pharma in 2018 (Patient Perspective) | Analysis on 30 Pharma Companies by 222 Neurological Patient Groups - GlobeNewswire October 24, 2019 The Corporate Reputation of Neurological Pharma in 2018 (Patient Perspective) | Analysis on 30 Pharma Companies by 222 Neurological Patient Groups GlobeNewswire
- Globin Protein Levels May Help Assess Efficacy of Dopamine Agonists in Parkinson’s Patients, Study Shows April 29, 2019 Evaluation of two specific proteins circulating in the blood, called alpha- and beta-globin, may help monitor treatment efficacy and risk of side effects among patients with Parkinson’s disease, a study suggests. The study, “2D-DIGE as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine-dictated states of Parkinson’s disease and schizophrenia,” was published in Neuropsychiatric Disease and Treatment. Parkinson’s…
- Monthly Research Review – November 2020 November 30, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Intec Pharma Granted Hong Kong Patent for Carbidopa/Levodopa Pill for Parkinson’s July 25, 2017 Hong Kong has issued a patent to Intec Pharma for its investigational Accordion Pill Carbidopa/Levodopa (AP-CD/LD) drug delivery for Parkinson’s disease symptoms in advanced patients. The patent (HK1158545) is titled “Carbidopa/Levodopa Gastroretentive Drug Delivery” and is scheduled to remain active until April 2029. The patent belongs to Intec’s IN-7 patent family that already includes patents in the U.S., European Union, China, Japan, South Africa, and…
- Global Parkinson's Disease Treatment Market 2020 : Company Details and Competitors Analysis of International Market with Growth 2025 - KSU | The Sentinel Newspaper January 7, 2021 Global Parkinson's Disease Treatment Market 2020 : Company Details and Competitors Analysis of International Market with Growth 2025 KSU | The Sentinel Newspaper
- Global Parkinson's Disease Market Analysis by Market Competitors, Region, Product & Application - CW57.TV July 2, 2019 Global Parkinson's Disease Market Analysis by Market Competitors, Region, Product & Application CW57.TVParkinson's Disease Market report covers the disease overview, definition, classification, symptoms, ethology, pathophysiology and diagnostic methods.
- Metformin reverses the schizophrenia-like behaviors induced by MK-801 in rats. May 24, 2019 Metformin reverses the schizophrenia-like behaviors induced by MK-801 in rats. Brain Res. 2019 May 20;: Authors: Wang X, Luo C, Mao XY, Li X, Yin JY, Zhang W, Zhou HH, Liu ZQ Abstract Schizophrenia is known to be a complex and disabling psychiatric disorder. Dopamine receptor antagonists have a significant therapeutic effect in improving the positive symptoms that are associated…